ClinicalTrials.gg
Active, not recruitingNCT05111353Updated Nov 3, 2026Results posted

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

A Phase 1 interventional study of Optimized neoantigen synthetic long peptide vaccine and Poly-ICLC in Pancreas Cancer, Pancreatic Cancer and Cancer of the Pancreas, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment

How we know

Updated Nov 3, 2026Now Active, not recruitingResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Pancreatic Neoplasms by Washington University School of Medicine — 4 open to participants now, 6 under way, none of them phase 3. Pancreatic Neoplasms · Washington University School of Medicine.

Enrollment
14th of 32
33 · median 27
Started
2022
with 1 other
Phase 1
14 of 34
2 open now
Registered
27th of 34
by date

Among the 34 studies in Pancreatic Neoplasms by Washington University School of Medicine, this one is the 14th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 in phase 1, and was the 27th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

4 of the 34 studies in Pancreatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Pancreatic Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

This is a randomized phase 1 clinical trial to evaluate the safety of an optimized neoantigen synthetic long peptide (SLP) vaccines in pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. Patients will be randomized to one of two arms: Arm 1 (neoantigen vaccine following neoadjuvant chemotherapy and surgery) or Arm 2 (neoantigen vaccine following neoadjuvant chemotherapy in the window prior to surgery).

Those who are ineligible for vaccine administration including those whose disease progresses or recurs during neoadjuvant chemo or who are otherwise unable to complete surgical resection but who had a personalized neoantigen vaccine manufactured, or significant progress has been made as determined by treating physician, are permitted to receive vaccine injections on study.

03

Conditions studied

  • Pancreas Cancer
  • Pancreatic Cancer
  • Cancer of the Pancreas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Step 0 Inclusion Criteria (A patient will be eligible for evaluation and sequencing of tissue for vaccine development only if ALL of the following criteria apply:)

  • or cytologically confirmed, newly diagnosed, treatment-naïve patients with localized or borderline resectable adenocarcinoma of the pancreas for whom chemotherapy is considered appropriate; mixed histology (including adenosquamous). Patients with clinical suspicion of pancreatic adenocarcinoma can be enrolled for pre-treatment , and must be histologically confirmed to have adenocarcinoma before being treated on study. Patients with squamous carcinoma or neuroendocrine tumor will be excluded.
  • Evaluable disease, in the opinion of the treating investigator or PI.
  • Tissue specimens available in sufficient quantity to allow for sequencing.
  • At least 18 years of age.
  • of > 12 months.
  • performance status ≤ 1
  • Adequate bone marrow and organ function as defined below:

    • WBC ≥ 1.5 K/cumm
    • ≥ 1.0 K/cumm
    • ≥ 50 K/cumm
    • ≥ 8.0 g/dL
    • total ≤ 5.0 X institutional
    • /ALT ≤ 5.0 X institutional upper limit of normal
    • creatinine ≤2.5 X institutional upper limit of normal OR ≥ 30 mL/min by Cockcroft-Gault for patients with creatinine levels above institutional normal
    • Note: labs can be repeated prior to chemo if needed.
    • Note: Patients who have had a stent placed for biliary obstruction and whose liver function is expected to improve may enroll provided serum bilirubin at time of enrollment is within the limits above.
  • (INR) and activated partial thromboplastin time (PTT) \< 2.0 x ULN provided the patient is not on anticoagulation therapy.
  • Women of and men must agree to use two forms of adequate prior to study entry, for the duration of study participation, and for 3 months after completion of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Able to understand and willing to sign an IRB approved written document.

Step 0 Exclusion Criteria (A patient will be eligible for evaluation and sequencing of tissue for vaccine development only if ALL of the following criteria apply:)

  • Evidence of predominantly neuroendocrine (defined by > 50% histology) tumor, pure neuroendocrine tumor, duodenal adenocarcinoma, or ampullary adenocarcinoma.
  • History of other ≤ 3 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only, carcinoma in situ of the cervix, or LCIS/DCIS of the breast.
  • Receiving any other agents, or planning to receive other investigational agents as part of neoadjuvant therapy.
  • Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.
  • Acute or chronic, hematologic, pulmonary, cardiovascular, hepatic renal, and/or other functional abnormality that might jeopardize the health and safety of the participant as determined by the investigator based on medical history, physical examination, laboratory values, and/or diagnostic studies. If needed and appropriate. the final determination related to study eligibility prior to the administration of the first vaccine will be documented by both the PI and Sub-Investigators in consultation with a specialist.
  • A psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and/or medical record
  • Prior or currently active disease requiring management with . This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., ) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or taking inhaled corticosteroids that does not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allow if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for > 7 consecutive days. Premedication for chemotherapy does not apply to this criteria and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if eligible.
  • Pregnant and/or breastfeeding.
  • Known -positive status.
  • History of positive test for virus surface antigen (HBsAg) and/or positive antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.

Step 1 Eligibility: At Step 1 eligibility confirmation prior to vaccination, the above criteria must be met plus:

  • Completed at least 4 months of neoadjuvant chemotherapy such as FOLFIRINOX, modified FOLFIRINOX, or gemcitabine + nab-paclitaxel. Dose modifications and/or delays in neoadjuvant chemotherapy may be made at the discretion of the treating physician
  • Reimaging within 4 weeks of last dose of chemotherapy demonstrates no evidence of progressive disease. Patients who progress on mFOLFIRINOX and transition to gemcitabine + nab-paclitaxel may still be eligible for vaccine administration at discretion of PI and treating MD provided they do not show progression following completion of chemotherapy and the patient continues to be eligible for surgical resection. Patients who, in the opinion of the treating physician, require SBRT prior to surgery will receive vaccine after surgery regardless of randomization.

    **Patients who progress or recur following neoadjuvant chemotherapy or who are otherwise unable to complete a surgical resection, but who still meet other Step 1 criteria, may still be eligible for vaccine administration with documented treating physician and PI approval.

  • There is a 1 week prior to Day 1 of vaccine for patients on daily systemic steroids at doses exceeding 10 mg prednisone.
  • Must not be receiving or have received any other investigational agents within the last 30 days. Note that patients who are receiving or will be receiving adjuvant chemotherapy are permitted to continue on study and are considered eligible.
  • Patients may not have received a within 30 days prior to the first day of treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed.
  • Sufficient wound healing per the evaluation of the treating physician.
  • If a patient experiences disease progression or recurrence during neoadjuvant chemotherapy, or is otherwise unable to complete a surgical resection after sufficient progress has been made on the vaccine production, the participant may still receive treatment with the peptide vaccine. Eligibility for continued participation in these cases will be at the treating physician and PI's discretion.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Arm 1: Vaccine given after neoadjuvant chemotherapy and surgery

    * The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given. * Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, 22, 50, and 78 beginning approximately 1 month after surgery. Day 1 should begin approximately 1 month after surgery.

    Biological: Optimized neoantigen synthetic long peptide vaccine · Biological: Poly-ICLC

  • Experimental
    Arm 2: Vaccine given after neoadjuvant chemotherapy but before surgery

    * The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given. * Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, and 22 during the chemotherapy holiday, and Days 50 and 78 post-operatively. Optimal timing for Day 1 is 1 week after end of chemotherapy, but Day 1 may be given up to 3 weeks after end of chemotherapy.

    Biological: Optimized neoantigen synthetic long peptide vaccine · Biological: Poly-ICLC

Interventions

  • BiologicalOptimized neoantigen synthetic long peptide vaccine

    Neoantigen vaccines will be provided on a patient-specific basis

  • BiologicalPoly-ICLC

    Poly-ICLC will be supplied by Oncovir, Inc.

    Also known as: Hiltonol

06

What researchers measure

Primary outcomes

  1. Safety of Neoantigen SLP Vaccine as Measured by Number of Subjects Experiencing Each Type of Adverse Event

    -Adverse events will be characterized according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE).

    Time frame: Through 4 weeks after completion of last vaccination (estimated to be 108 days)

Secondary outcomes

  1. Immunogenicity of Neoantigen Peptide Vaccine as Measured by the the Number of Neoantigen-specific T Cells (Only Arm 1 and Arm 2)

    * Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.

    Time frame: Through approximately 2 years and 78 days

  2. Immunogenicity of Neoantigen Peptide Vaccine as Measured by the Phenotype of Neoantigen-specific T Cells (Only Arm 1 and Arm 2)

    * Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.

    Time frame: Through approximately 2 years and 78 days

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery
Started1914
Completed98
Not completed106
Withdrew: Did not start treatment - biopsy did not provide sufficient rna yield53
Withdrew: Withdrawal by subject11
Withdrew: Did not start treatment - tumor cellularity extremely low10
Withdrew: Did not start treatment - participant withdrawal11
Withdrew: Did not start treatment - disease progression11
Withdrew: Did not start treatment - physician decision10

Outcome measures

PrimarySafety of Neoantigen SLP Vaccine as Measured by Number of Subjects Experiencing Each Type of Adverse Event

-Adverse events will be characterized according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE).

Time frame:
Through 4 weeks after completion of last vaccination (estimated to be 108 days)
Reported as:
Count of participants · Participants
Safety of Neoantigen SLP Vaccine as Measured by Number of Subjects Experiencing Each Type of Adverse Event
ParticipantsArm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery
Grade 1/2 anemia24
Grade 3/4/5 anemia12
Grade 1/2 eosinophilia01
Grade 3/4/5 myocardial infarction10
Grade 1/2 double vision10
Grade 1/2 abdominal cramping01
Grade 1/2 abdominal pain23
Grade 1/2 colitis10
Grade 1/2 constipation10
Grade 1/2 diarrhea21
Grade 1/2 dyspepsia10
Grade 1/2 gastroparesis01
Grade 1/2 mouth sore01
Grade 1/2 mucositis oral30
Grade 1/2 nausea45
Grade 1/2 vomiting44
Grade 1/2 arm pain01
Grade 1/2 body aches01
Grade 1/2 chills44
Grade 1/2 edema limbs12
Grade 1/2 fatigue56
Grade 1/2 fever43
Grade 1/2 flu like symptoms12
Grade 1/2 injection site pain in arms and legs01
Grade 1/2 injection site reaction85
Grade 1/2 sore arm01
Grade 1/2 bacteremia01
Grade 1/2 COVID-1910
Grade 1/2 gum infection11
Grade 1/2 herpes simplex reactivation01
Grade 1/2 urinary tract infection01
Grade 1/2 alanine aminotransferase increased24
Grade 3/4/5 alanine aminotransferase increased01
Grade 1/2 alkaline phosphatase increased23
Grade 3/4/5 alkaline phosphatase increased01
Grade 1/2 aspartate aminotransferase increased26
Grade 3/4/5 aspartate aminotransferase increased10
Grade 1/2 blood bilirubin increased01
Grade 1/2 blood lactate dehydrogenase increased10
Grade 1/2 creatinine increased10
Grade 3/4/5 creatinine increased01
Grade 1/2 INR increased01
Grade 1/2 lymphocyte count decreased12
Grade 1/2 neutrophil count decreased11
Grade 3/4/5 neutrophil count decreased10
Grade 1/2 platelet count decreased11
Grade 3/4/5 platelet count decreased01
Grade 1/2 thyroid stimulating hormone increased10
Grade 1/2 weight loss12
Grade 1/2 white blood cell decreased32
Grade 1/2 anorexia31
Grade 3/4/5 anorexia01
Grade 1/2 hyperglycemia36
Grade 1/2 hypermagnesemia01
Grade 1/2 hypernatremia01
Grade 1/2 hyperphosphatemia03
Grade 1/2 hypoalbuminemia22
Grade 3/4/5 hypoalbuminemia01
Grade 1/2 hypocalcemia23
Grade 1/2 hypoglycemia01
Grade 1/2 hypokalemia22
Grade 3/4/5 hypokalemia01
Grade 1/2 hyponatremia12
Grade 1/2 hypophosphatemia02
Grade 1/2 arthralgia30
Grade 1/2 buttock pain01
Grade 1/2 generalized muscle weakness10
Grade 3/4/5 generalized muscle weakness01
Grade 1/2 myalgia30
Grade 1/2 dizziness21
Grade 1/2 dysgeusia11
Grade 1/2 headache04
Grade 3/4/5 headache01
Grade 3/4/5 intracranial hemorrhage01
Grade 1/2 peripheral sensory neuropathy22
Grade 1/2 tremor10
Grade 1/2 anxiety01
Grade 1/2 depression11
Grade 3/4/5 chronic kidney disease01
Grade 1/2 urinary frequency01
Grade 1/2 dyspnea12
Grade 1/2 sore throat10
Grade 1/2 alopecia01
Grade 1/2 dry lips10
Grade 1/2 dry skin10
Grade 1/2 hyperhidrosis10
Grade 1/2 itching on face01
Grade 1/2 rash maculo-papular01
Grade 1/2 skin hyperpigmentation10
Grade 1/2 hypertension11
Grade 3/4/5 hypertension01
Grade 1/2 hypotension10
Grade 3/4/5 thromboembolic event01
SecondaryImmunogenicity of Neoantigen Peptide Vaccine as Measured by the the Number of Neoantigen-specific T Cells (Only Arm 1 and Arm 2)

* Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.

Time frame:
Through approximately 2 years and 78 days

Results for this outcome have not been posted.

SecondaryImmunogenicity of Neoantigen Peptide Vaccine as Measured by the Phenotype of Neoantigen-specific T Cells (Only Arm 1 and Arm 2)

* Immune monitoring will occur at baseline, at time of surgery, day 1, day 15, day 22, day 50, and day 78 for Arm 1. Optional monitoring at 1 and 2 years after last vaccine administration * Immune monitoring will occur at baseline, day 1, day 15, day 22, day 50, at the time of surgery, and day 78 for Arm 2. Optional monitoring at 1 and 2 years after last vaccine administration.

Time frame:
Through approximately 2 years and 78 days

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were collected from first dose of vaccine through 4 weeks after the last vaccination (up to 78 days and 4 weeks). All-cause mortality is collected from first dose of vaccine through completion of follow-up (up to 2 years and 78 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and Surgery4/10 (40%)1/10 (10%)10/10 (100%)
Arm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery3/9 (33.3%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventArm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery
GastroparesisGastrointestinal disorders0/101/9
BacteremiaInfections and infestations0/101/9
Generalized muscle weaknessMusculoskeletal and connective tissue disorders0/101/9
HeadacheNervous system disorders0/101/9
Intracranial hemorrhageNervous system disorders0/101/9
HypertensionVascular disorders0/101/9
Thromboembolic eventVascular disorders0/101/9
Myocardial infarctionCardiac disorders1/100/9
Most frequent other events
Showing 10 of 75
Most frequent other events
EventArm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before Surgery
Injection site reactionGeneral disorders8/105/9
AnemiaBlood and lymphatic system disorders3/106/9
FatigueGeneral disorders5/106/9
Aspartate aminotransferase increasedInvestigations3/106/9
HyperglycemiaMetabolism and nutrition disorders3/106/9
NauseaGastrointestinal disorders4/105/9
Alanine aminotransferase increasedInvestigations2/105/9
VomitingGastrointestinal disorders4/104/9
ChillsGeneral disorders4/104/9
Alkaline phosphatase increasedInvestigations2/104/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before SurgeryTotal
Median69 (56 to 81)65.5 (47 to 80)68 (47 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before SurgeryTotal
Female12315
Male71118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before SurgeryTotal
Hispanic or Latino202
Not Hispanic or Latino171431
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before SurgeryTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White161430
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Arm 1: Vaccine Given After Neoadjuvant Chemotherapy and SurgeryArm 2: Vaccine Given After Neoadjuvant Chemotherapy But Before SurgeryTotal
United States191433
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Sequencing data will be submitted to the database of Genotypes and Phenotypes (dbGap) at the National Cancer Institute.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Nov 2025, 34 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 209 non-industry phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 74. This study's 34 months is below that.

Counting every sponsor, half of 380 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Oct 2027, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2021
First posted
Nov 8, 2021
StartActual
Dec 15, 2022
Primary completionActual
Nov 3, 2025
CompletionEst.
Oct 6, 2027was Nov 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Active, not recruiting
changed Nov 3, 2026
Results
Results posted
posted Nov 3, 2026
Study completion
Nov 3, 2025→Oct 6, 2027
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedSafety of neoantigenNeoantigen SLP vaccineVaccine as measuredMeasured by numberNumber of subjects experiencing each typeSubjects Experiencing Each Type of adverse eventAdverse EventTime frame: Through 4 weeks after completion of last vaccination (estimated to be 108 days)
Nov 3, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedImmunogenicity of neoantigen peptide vaccineNeoantigen Peptide Vaccine as measuredMeasured by the the numberNumber of neoantigenNeoantigen-specific T cellsCells (onlyOnly Arm 1 and Arm 2)Time frame: Through approximately 2 years and 78 days
  • EditedImmunogenicity of neoantigen peptide vaccineNeoantigen Peptide Vaccine as measuredMeasured by the phenotypePhenotype of neoantigenNeoantigen-specific T cellsCells (onlyOnly Arm 1 and Arm 2)Time frame: Through approximately 2 years and 78 days
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Completed→Active, not recruiting
    Results posted
    Study completion Nov 3, 2025→Oct 6, 2027
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedSafety of neoantigenNeoantigen SLP vaccineVaccine as measuredMeasured by numberNumber of subjects experiencing each typeSubjects Experiencing Each Type of adverse eventAdverse EventTime frame: Through 4 weeks after completion of last vaccination (estimated to be 108 days)
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedImmunogenicity of neoantigen peptide vaccineNeoantigen Peptide Vaccine as measuredMeasured by the the numberNumber of neoantigenNeoantigen-specific T cellsCells (onlyOnly Arm 1 and Arm 2)Time frame: Through approximately 2 years and 78 days
    • EditedImmunogenicity of neoantigen peptide vaccineNeoantigen Peptide Vaccine as measuredMeasured by the phenotypePhenotype of neoantigenNeoantigen-specific T cellsCells (onlyOnly Arm 1 and Arm 2)Time frame: Through approximately 2 years and 78 days
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05111353
Collaborators
National Cancer Institute (NCI), Leidos, UNICO Foundation, The Foundation for Barnes-Jewish Hospital
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Dec 15, 2022
Primary completion
Nov 3, 2025
Completion
Oct 6, 2027 (estimated)
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

William E Gillanders, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poly ICLC

Start the discussion